Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax has experienced a notable decline in its stock price over the past week, dropping by 8.82%. This downturn comes amidst a challenging landscape for the company, as Citi ini ...

Novavax (NVAX) closed at $6.41 in the latest trading session, marking a +1.75% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.22%. On the other hand, the ...

Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Novavax is expected to post a loss of $0.12 per ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Shares of Novavax Inc. NVAX slid 7.68% to $6.49 Tuesday, on what proved to be an all-around poor trading session for the ...

Novavax (NASDAQ:NVAX) on Wednesday announced late-stage trial data to indicate that its COVID-19-Influenza Combination (CIC) vaccine candidate and its stand-alone influenza vaccine candidate generated ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

This was the stock's second consecutive day of losses.